Zydus Launches India's First NCE "Lipaglyn" – RTT News
Zydus Launches India’s First NCE “Lipaglyn”
RTT News Wit a non-renal route of elimination, Lipaglyn has no adverse events like edema, weight gain, myopathies or derangement of liver and/or kidney functions, thus making it safe and efficacious. Lipaglyn is recommended for once daily administration as a 4 … |